AdCMVCD

AdCMVCD is a replication-deficient adenoviral vector designed for suicide gene therapy. It contains the *Escherichia coli* cytosine deaminase (CD) gene under the transcriptional control of the cytomegalovirus (CMV) early promoter. When injected into a tumor, the vector transduces neoplastic cells, causing them to express the CD enzyme. This enzyme then converts the subsequently administered non-toxic prodrug 5-fluorocytosine (5-FC) into 5-fluorouracil (5-FU), a potent antimetabolite. This approach generates high local concentrations of 5-FU within the tumor microenvironment, enhancing anti-tumor efficacy while minimizing the systemic toxicities typically associated with intravenous 5-FU chemotherapy. AdCMVCD has been investigated in clinical and preclinical settings for the treatment of various solid tumors, including prostate cancer, pancreatic cancer, and malignant gliomas.

Other names

Adenovirus-mediated cytosine deaminaseAd-CD